Clinical Trial Update: Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma [Phase 2]

View source ↗

Summary

This Phase 2 trial update indicates completion of a first-line therapy approach for HER2-negative gastric/GEJ adenocarcinoma using chemotherapy and pembrolizuma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Junction Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Esophagogastric Adenocarcinoma | Phase 2 | Status: COMPLETED